A Prospective, Phase II, Single-arm Study to Evaluate The Safety and Efficacy of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Latest Information Update: 06 Oct 2023
At a glance
- Drugs Donafenib (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 02 Dec 2021 New trial record